by Heidi Moseson, Ruvani Jayaweera,Ijeoma Egwuatu, Belén Grosso, Ika Ayu Kristianingrum, Sybil Nmezi, Ruth Zurbriggen, Relebohile Motana, Chiara Bercu, Sofía Carbone, Caitlin Gerdts
The Lancet Global Health, 18 November 2021 (Open access)
Background – Clinical trials have established the high effectiveness and safety of medication abortion in clinical settings. However, barriers to clinical abortion care have shifted most medication abortion use to out-of-clinic settings, especially in the context of the COVID-19 pandemic. Given this shift, we aimed to estimate the effectiveness of self-managed medication abortion (medication abortion without clinical support), and to compare it to effectiveness of clinician-managed medication abortion.
Methods – For this prospective, observational cohort study, we recruited callers from two safe abortion accompaniment groups in Argentina and Nigeria who requested information on self-managed medication abortion. Before using one of two medication regimens (misoprostol alone or in combination with mifepristone), participants completed a baseline survey, and then two follow-up phone surveys at 1 week and 3 weeks after taking pills. The primary outcome was the proportion of participants reporting a complete abortion without surgical intervention. Legal restrictions precluded enrolment of a concurrent clinical control group; thus, a non-inferiority analysis compared abortion completion among those in our self-managed medication abortion cohort with abortion completion reported in historical clinical trials using the same medication regimens, restricted to participants with pregnancies of less than 9 weeks’ gestation. This study was registered with ISCRTN, ISRCTN95769543.
Findings – Between July 31, 2019, and April 27, 2020, we enrolled 1051 participants. We analysed abortion outcomes for 961 participants, with an additional 47 participants reached after the study period. Most pregnancies were less than 12 weeks’ duration. Participants in follow-up self-managed their abortions using misoprostol alone (593 participants) or the combined regimen of misoprostol plus mifepristone (356 participants). At last follow-up, 586 (99%) misoprostol alone users and 334 (94%) combined regimen users had a complete abortion without surgical intervention. For those with pregnancies of less than 9 weeks’ gestation, both regimens were non-inferior to medication abortion effectiveness in clinical settings.
Interpretation – Findings from this prospective cohort study show that self-managed medication abortion with accompaniment group support is highly effective and, for those with pregnancies of less than 9 weeks’ gestation, non-inferior to the effectiveness of clinician-managed medication abortion administered in a clinical setting. These findings support the use of remote self-managed models of early abortion care, as well as telemedicine, as is being considered in several countries because of the COVID-19 pandemic.
Authors’ Note: It is with enormous pride and appreciation for years of collaboration with our accompaniment group colleagues that we share the news that main findings from Ibis Reproductive Health’s landmark study were published today in the Lancet Global Health. In close collaboration with safe abortion advocates at GIWYN, La Revuelta and Samsara, we worked as a global, inter-disciplinary research/activist partnership through each and every step of this first-of-its-kind study.
With data collected from accompaniment group callers in Argentina and Nigeria, we found that self-managed abortion (SMA) with medications and accompaniment group support was highly effective and safe:
- 93.8% of those who used the mifepristone + misoprostol regimen had a complete abortion without surgical intervention.
- 98.8% of those who used the misoprostol-alone regimen had a complete abortion without surgical intervention.
The findings in this paper establish that self-managed medical abortion with accompaniment support is no less effective than clinician-managed medical abortion in clinic settings, and that the effectiveness of SMA with misoprostol alone is highly effective, and warrants renewed attention.
We’d greatly appreciate your support in spreading the word about the findings and have put together a collection of resources that we hope will be useful: